Now, almost two years after the Canadian launch of the first PCSK9i, actual claims experience shows that the overall impact of this drug class on the private payer market has in reality been minimal.
This can be attributed to both appropriate and responsible prescribing by clinicians as well as the effective claims management by insurers. In essence, the right patients are truly receiving these products.
Satwik Misra, CFA, MBA will be stepping into the newly created role of Director, Consultant Relationships & Business Initiatives, reflecting the continued growth and expansion...
The Pension Investment Association of Canada, alongside the Canadian Life and Health Insurance Association and the Portfolio Management Association of Canada, is asking the Senate to...
Kate Nazar recently joined Canada Life as vice-president, Group Retirement Services. In this newly created role, Kate will take on a holistic approach and be...
An article on incoming changes to Nova Scotia’s provincial Pension Benefits Act was the most-read story on BenefitsCanada.com this past week. Here are the top five...
While seven in 10 (70 per cent) Canadian employees say their employer does a good job of fostering a safe and trusting environment that encourages...
Increased deal-making in the Canadian annuities market is adding pressure to defined benefit plan sponsors seeking to de-risk their plans, says Jason Vary, president of...
The percentage of claimants filing claims for obesity drugs increased by 43 per cent in 2023, according to a new report by GreenShield. The report,...
The Public Sector Pension Investment Board, along with partner Investcorp, is investing in accounting firm PKF O’Connor Davies LLP. According to a press release, the...